Search Results

Showing 501 - 520 results of 50,622,107 for search '', query time: 4.66s Refine Results
  1. 501
    Staff View Links
    In:
    International Ophthalmology, Springer Science and Business Media LLC, Vol. 42, No. 6 ( 2022-06), p. 1669-1677
    Type of Medium:
    Online Resource
    ISSN:
    1573-2630
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2022
    detail.hit.zdb_id:
    2009810-8
    Crossref
  2. 502
    Staff View Links
    In:
    International Ophthalmology, Springer Science and Business Media LLC, Vol. 42, No. 7 ( 2022-07), p. 2205-2218
    Type of Medium:
    Online Resource
    ISSN:
    1573-2630
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2022
    detail.hit.zdb_id:
    2009810-8
    Crossref
  3. 503
    Staff View Links
    In:
    International Ophthalmology, Springer Science and Business Media LLC, Vol. 42, No. 8 ( 2022-08), p. 2417-2424
    Type of Medium:
    Online Resource
    ISSN:
    1573-2630
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2022
    detail.hit.zdb_id:
    2009810-8
    Crossref
  4. 504
    Staff View Links
    In:
    International Ophthalmology, Springer Science and Business Media LLC, Vol. 42, No. 7 ( 2022-07), p. 2039-2046
    Type of Medium:
    Online Resource
    ISSN:
    1573-2630
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2022
    detail.hit.zdb_id:
    2009810-8
    Crossref
  5. 505
    Staff View Links
    In:
    International Ophthalmology, Springer Science and Business Media LLC, Vol. 42, No. 6 ( 2022-06), p. 1927-1938
    Type of Medium:
    Online Resource
    ISSN:
    1573-2630
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2022
    detail.hit.zdb_id:
    2009810-8
    Crossref
  6. 506
    Staff View Links
    In:
    International Ophthalmology, Springer Science and Business Media LLC, Vol. 42, No. 8 ( 2022-08), p. 2459-2472
    Abstract:
    This study evaluated the clinical safety and efficacy of tanfanercept (HBM9036) ophthalmic solution as a novel treatment for dry eye disease (DED) in a controlled adverse environment (CAE) study conducted in China. Methods In a single-center, double-masked, randomized, placebo-controlled study, 100 patients received 0.25% tanfanercept, or placebo, twice daily for eight weeks. A mobile international CAE ® DE Model was used for patient selection with a standardized challenge endpoint. Primary efficacy endpoint was fluorescein inferior corneal staining score (ICSS) pre- to post-CAE challenge from baseline. Secondary endpoints included Schirmer’s Tear Test, Tear-Film Break-Up Time, Ocular Discomfort Score, Ora Calibra ® Ocular Discomfort and 4-Symptom Questionnaire, total corneal staining score (TCSS), and drop comfort. Signs and symptoms were assessed both pre- and post-CAE to evaluate the efficacy of tanfanercept on both environmental and CAE endpoints. Results The tanfanercept treatment group showed improvement in ICSS pre- to post-CAE change from baseline scores when compared to placebo (− 0.61 ± 0.11 and − 0.54 ± 0.11, respectively; mean difference = 0.07, p  = 0.65). TCSS pre–post-CAE change from baseline scores was also in favor of active when compared to placebo (− 1.03 ± 0.21 and − 0.67 ± 0.21, respectively; mean difference = 0.37, p  = 0.23). Schirmer’s score improvement was demonstrated in favor of active (1.87 ± 0.62 mm) as compared to placebo (1.28 ± 0.62 mm; mean difference = 0.59 mm, p  = 0.50). Change from baseline in mean Tear-Film Break-up Time favored active treatment over placebo (mean difference = 1.21 s, p  = 0.45). Notably, the tanfanercept showed more obvious benefits for each DED sign in a subgroup of subjects ≥ 35 years of age. Tanfanercept was well tolerated with no serious adverse events occurring during the study. Conclusion Tanfanercept demonstrated improvements in favor of active as compared to placebo in the signs of DED, being safe and well tolerated. These data support further evaluation of tanfanercept for the treatment of DED in China. Trial registration This study was retrospectively registered at ClinicalTrials.gov (NCT04092907) on September 17, 2019.
    Type of Medium:
    Online Resource
    ISSN:
    1573-2630
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2022
    detail.hit.zdb_id:
    2009810-8
    Crossref
  7. 507
    Staff View Links
    In:
    International Ophthalmology, Springer Science and Business Media LLC, Vol. 42, No. 9 ( 2022-03-30), p. 2785-2799
    Type of Medium:
    Online Resource
    ISSN:
    1573-2630
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2022
    detail.hit.zdb_id:
    2009810-8
    Crossref
  8. 508
    Staff View Links
    In:
    International Ophthalmology, Springer Science and Business Media LLC, Vol. 42, No. 8 ( 2022-08), p. 2501-2509
    Type of Medium:
    Online Resource
    ISSN:
    1573-2630
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2022
    detail.hit.zdb_id:
    2009810-8
    Crossref
  9. 509
    Staff View Links
    In:
    Breast Cancer Research and Treatment, Springer Science and Business Media LLC, Vol. 78, No. 1 ( 2003-3), p. 37-44
    Type of Medium:
    Online Resource
    ISSN:
    0167-6806, 1573-7217
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2003
    detail.hit.zdb_id:
    2004077-5
    Crossref
  10. 510
    Staff View Links
    In:
    Breast Cancer Research and Treatment, Springer Science and Business Media LLC, Vol. 78, No. 1 ( 2003-3), p. 45-50
    Type of Medium:
    Online Resource
    ISSN:
    0167-6806, 1573-7217
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2003
    detail.hit.zdb_id:
    2004077-5
    Crossref
  11. 511
    Staff View Links
    In:
    Breast Cancer Research and Treatment, Springer Science and Business Media LLC, Vol. 78, No. 1 ( 2003-3), p. 133-134
    Type of Medium:
    Online Resource
    ISSN:
    0167-6806, 1573-7217
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2003
    detail.hit.zdb_id:
    2004077-5
    Crossref
  12. 512
    Staff View Links
    In:
    Breast Cancer Research and Treatment, Springer Science and Business Media LLC, Vol. 78, No. 1 ( 2003-3), p. 89-96
    Type of Medium:
    Online Resource
    ISSN:
    0167-6806, 1573-7217
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2003
    detail.hit.zdb_id:
    2004077-5
    Crossref
  13. 513
    Staff View Links
    In:
    Breast Cancer Research and Treatment, Springer Science and Business Media LLC, Vol. 78, No. 1 ( 2003-3), p. 97-103
    Type of Medium:
    Online Resource
    ISSN:
    0167-6806, 1573-7217
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2003
    detail.hit.zdb_id:
    2004077-5
    Crossref
  14. 514
    Staff View Links
    In:
    Breast Cancer Research and Treatment, Springer Science and Business Media LLC, Vol. 78, No. 1 ( 2003-3), p. 119-126
    Type of Medium:
    Online Resource
    ISSN:
    0167-6806, 1573-7217
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2003
    detail.hit.zdb_id:
    2004077-5
    Crossref
  15. 515
    Staff View Links
    In:
    Breast Cancer Research and Treatment, Springer Science and Business Media LLC, Vol. 78, No. 3 ( 2003-4), p. 299-311
    Type of Medium:
    Online Resource
    ISSN:
    0167-6806, 1573-7217
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2003
    detail.hit.zdb_id:
    2004077-5
    Crossref
  16. 516
    Staff View Links
    In:
    International Ophthalmology, Springer Science and Business Media LLC, Vol. 42, No. 10 ( 2022-04-01), p. 3071-3077
    Type of Medium:
    Online Resource
    ISSN:
    1573-2630
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2022
    detail.hit.zdb_id:
    2009810-8
    Crossref
  17. 517
    Staff View Links
    In:
    International Ophthalmology, Springer Science and Business Media LLC, Vol. 42, No. 8 ( 2022-08), p. 2599-2607
    Type of Medium:
    Online Resource
    ISSN:
    1573-2630
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2022
    detail.hit.zdb_id:
    2009810-8
    Crossref
  18. 518
    Staff View Links
    In:
    Breast Cancer Research and Treatment, Springer Science and Business Media LLC, Vol. 78, No. 3 ( 2003-4), p. 337-345
    Type of Medium:
    Online Resource
    ISSN:
    0167-6806, 1573-7217
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2003
    detail.hit.zdb_id:
    2004077-5
    Crossref
  19. 519
    Staff View Links
    In:
    International Ophthalmology, Springer Science and Business Media LLC, Vol. 42, No. 9 ( 2022-04-02), p. 2939-2947
    Abstract:
    To compare binocular anterior segment structures in Chinese patients with dark iris and unilateral Fuchs’ uveitis syndrome (FUS). Methods This was a cross-sectional study including 34 phakic eyes (17 patients) with unilateral FUS. Anterior segment parameters were measured by rotating Scheimpflug imaging camera, noncontact specular microscopy, and anterior segment optical coherence tomography. Results Corneal volume was higher in FUS eyes compared to unaffected eyes ( p   〈  0.05). The iridocorneal angles were larger in FUS eyes compared to contralateral eyes ( p   〈  0.05). Mean endothelial cell density (ECD) was lower, and the coefficient of variation in endothelial cell size and average cell area of endothelial cells (ACA) were higher, in FUS eyes ( p   〈  0.05). Mean densitometry values of the midstromal cornea (zones with a diameter of 0–2, 2–6, or 10–12 mm), posterior (0–2, 2–6, 10–12, or 0–12 mm), or total thickness (0–2 or 2–6 mm) were higher in FUS eyes compared with unaffected eyes ( p   〈  0.05). ECD, percentage of hexagonal cells, and ACA were strongly related to densitometry values of the midstromal and posterior cornea in the FUS eyes ( p   〈  0.05). Smoothness index of iris was lager in affected eyes ( p   〈  0.05). Conclusion In Chinese patients with unilateral FUS, loss of endothelial cells, wider iridocorneal angle, thicker cornea, higher corneal densitometry of midstromal and posterior layer, and smoother iris were observed in affected eyes compared to contralateral eyes. These data can help to elucidate anterior segment characteristics of unilateral FUS in this population.
    Type of Medium:
    Online Resource
    ISSN:
    1573-2630
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2022
    detail.hit.zdb_id:
    2009810-8
    Crossref
  20. 520
    Staff View Links
    In:
    International Ophthalmology, Springer Science and Business Media LLC, Vol. 42, No. 10 ( 2022-04-05), p. 3061-3070
    Type of Medium:
    Online Resource
    ISSN:
    1573-2630
    URL:
    DOI:
    Language:
    English
    Publisher:
    Springer Science and Business Media LLC
    Publication Date:
    2022
    detail.hit.zdb_id:
    2009810-8
    Crossref